Overview:
Activation of the PI3K/AKT/mTOR signaling pathway has emerged as a central driver of resistance, with pathway alterations or overactivation identified in approximately half of patients with HR+/HER2- metastatic breast cancer. The expanding availability of PI3K, AKT, and PTEN-targeted therapies offers new opportunities—but also introduces complexity.
This engaging, fast-paced, and interactive Hot Seat program
will equip oncologists with a practical, evidence-based framework for
integrating pathway-targeted therapies into clinical practice. Faculty will
examine the latest clinical trial data, compare distinct toxicity profiles, and
discuss optimal sequencing strategies and patient selection in the context of
evolving treatment paradigms. Through case-based discussion and expert insight,
participants will gain clarity and confidence in personalizing care for
patients with advanced HR+/HER2- breast cancer.
Learning Objectives:
Upon completion of this activity, participants will be able to:
- Describe the rationale for targeting the PI3K/AKT/PTEN signaling pathway in the treatment of HR+/HER2- metastatic breast cancer (mBC)
- Apply best practices for molecular testing to identify actionable PI3K/AKT/PTEN pathway alterations in patients with HR+/HER2- mBC
- Integrate recent clinical trial evidence into the selection and sequencing of PI3K/AKT/PTEN pathway inhibitors for patients with HR+/HER2- mBC
- Implement evidence-based strategies to prevent, recognize, and manage adverse events associated with PI3K/AKT/PTEN pathway inhibitors
Target Audience:
This educational activity is directed toward medical
oncologists, advanced practice providers, nurses, pathologists, pharmacists,
and other HCPs involved in the management of metastatic breast cancer.
Rebecca Shatsky, MD
Professor of Medicine
Breast Medical Oncology Team Leader
Director of Breast Cancer Clinical Trials
Director of Inflammatory and Triple Negative Breast Cancer Program
University of California, San Diego
San Diego, CA
Maxwell Roger Lloyd, MD
Clinical Fellow in Medicine
Beth Israel Deaconess Medical Center
Boston, MA
Sarah Sammons, MD
Assistant Professor of Medicine
Harvard Medical School
Associate Director, Metastatic Breast Cancer Program
Dana-Farber Cancer Institute
Boston, MA
Sherry Shen, MD
Assistant Attending Physician
Co-Lead, Lobular Breast Cancer Program
Memorial Sloan Kettering Cancer Center
New York, NY
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.25 Contact Hours.